A phase 2, randomized, double-blind, placebo-controlled study to assess the tolerability and pharmacodynamic effects of CRD-740, a PDE9 inhibitor, in participants with chronic heart failure

Back

ESC Professional Premium Access

A phase 2, randomized, double-blind, placebo-controlled study to assess the tolerability and pharmacodynamic effects of CRD-740, a PDE9 inhibitor, in participants with chronic heart failure

Session: Heart failure: bench to bedside

Topic: Pharmacotherapy

Speaker: Professor J. Udelson (Boston, US)

Event: ESC Congress 2024

Congress Presentation

Add to my library

About the speaker

Professor James E Udelson

Tufts Medical Center, Inc., Boston (United States of America)

7 presentations

0 follower

9 more presentations in this session

Dual pathway inhibition in patients with atherosclerosis with and without heart failure: insights from the XATOA Registry

Speaker: Doctor P. Gouda (Edmonton, CA)

A newly developed small-molecule ErbB4 agonist reduces reactive cardiac fibrosis and adverse ventricular remodelling after myocardial infarction in a sex-specific manner.

Speaker: Miss B. Goovaerts (Antwerp, BE)

Unmasking patients insight into SGLT2 inhibitors- a collaborative quality improvement project to enhance patient education and safety

Speaker: Doctor L. Saad (Coventry, GB)

Long-acting CRF2 receptor agonist COR-1389 improves cardiopulmonary function parameters in monocrotaline-induced pulmonary hypertension and right heart failure rat model

Speaker: Doctor M. Kowala (Zionsville, US)

Heart failure treatment in the last years of life - a nationwide study of 364,000 individuals

Speaker: Doctor D. Lindholm (Norrtalje, SE)

Access the full session

Heart failure: bench to bedside

Speakers: Professor J. Udelson, Doctor P. Gouda, Miss B. Goovaerts, Doctor L. Saad, Doctor M. Kowala...

Access

About the event

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources